mitochondrial protease clpp

THX6 is an activator of human mitochondrial protease ClpP, with an EC50 of 1.18 μM. It displays cytotoxicity in ONC201-resistant SU-DIPG-VI cells, with an IC50 of 0.13 μM. THX6 inhibits the expression of mitochondria-related proteins (such as parkin, TFAM, NRF1, SDHA), leading to impaired mitochondrial function. Additionally, THX6 affects cell membrane lipid metabolism and exhibits antitumor potential.

ZG36, a human Caseinolytic protease P (ClpP) agonist, non-selectively degrades respiratory chain complexes and reduces mitochondrial DNA, causing mitochondrial dysfunction and inducing leukemic cell death. Additionally, it inhibits the development of acute myeloid leukemia in a xenograft mouse model [1].

TR-107 (Anticancer agent 230) is a selective and potent activator of the mitochondrial protease ClpP that inhibits tumor growth in the MDA-MB-231 xenograft model.